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from an average of 7.8 to 16.4 DDD/capita between 1999 and 2008. Three groups of
countries were identified: high, medium and low use of antidepressants countries.
Overall, antidepressant growth was observed (41% to 325% range) and was more
pronounced in low-use countries. By 2008, SSRIs were the predominant class in all
countries; followed by SNRIs whereas TCAs consumption went down. Over the
studied period, GDP and HE growth were aligned across countries; PE growth was
associated with antidepressant expenditures. CONCLUSIONS: Countries with
lower GDP / capita (and higher GDP growth) and lower baseline antidepressant
volumes are heading in the same direction as the higher income countries did in
the past, recording a 200-300% volume growth between 1999 and 2008). This offers
a unique opportunity tomonitor the anticipated health outcomes of their prescrip-
tion, which were missed in the past and which are valuable for future mental
health policy.
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OBJECTIVES: Sleep deprivation and disturbances can result in lowered productiv-
ity and increased errors/accidents. Existing research has documented higher use of
sleepmediations amongwomen; however, little is known about other factors such
as race, ethnicity and its association with the use of sleepmedications in a nation-
ally representative study sample. The objective of this study was to investigate the
relationship of various factors such as race, ethnicity, gender, employment status
with the use of sleepmedications in the US population.METHODS:A retrospective,
cross-sectional study design was used. Data from the 2009 Medical Expenditure
Panel Survey, a nationally representative survey of US population, were used for
this analysis. The study population included all survey respondents over the age of
18. A multiple logistic regression model was built to analyze odds of reporting use
of prescription or non prescription sleep medication. RESULTS: Of the total 20568
survey respondents, 8.28% (n 1703) used some type of medication to fall asleep in
the year 2009. The odds of reporting use of sleep medication were significantly
higher among females (OR1.404 CI 1.254-1.571) compared to males. The odds of
sleepmedication use were significantly lower among African American (OR 0.529
CI 0.453-0.617), Asian American (OR 0.387 CI 0.283-0.530) and Hispanic (OR 0.717
CI 0.621- 0.828) women compared to Non Hispanic Caucasian women. Unemploy-
ment (OR1.909 CI 1.674-2.178) and depression (OR5.009 CI 4.446-5.643) were
highly correlated with use of sleep medications. Additionally, compared to lower
income levels, higher income levels had lower odds of sleep medication use.
CONCLUSIONS: Unemployed Non-Hispanic Caucasian women in low income
households are more likely to use prescription or non prescription sleep medica-
tions. Further research on why such differences exist is necessary. The factors
identified in this study should be further investigated to identify vulnerable popu-
lations to investigate underlying causes of sleep disorders.
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OBJECTIVES: To evaluate daily average consumption (DACON) and average daily
costs (ADC) of duloxetine for patients with various pain and mood conditions sub-
sequent to the recent FDA approval of duloxetine in the management of chronic
musculoskeletal pain.METHODS: Retrospective analysis of commercially insured
patients prescribed duloxetine between January 1, 2011 and September 30, 2011
using the IMS Longitudinal Prescription and Medical Claims Database. This analy-
sis focused on patients diagnosed with only one of the following: chronic lower
back pain (CLBP), osteoarthritis (OA), fibromyalgia (FM), diabetic peripheral neuro-
pathic pain (DPNP), major depressive disorder (MDD), and generalized anxiety dis-
order (GAD). Patients were assigned to study cohorts based on ICD-9 codes re-
corded within -180/07 days of the date of the first duloxetine prescription filled
during the study interval. DACONs were defined as weighted averages of the total
number of pills dispensed by total days of supply across pill strength for all patients
within each cohort. DACONs were converted to ADCs using January 2011 average
wholesale prices (AWP). A second analysis based on prescriptions between January
1, 2010 and September 30, 2010 was conducted for comparative purposes.
RESULTS: A total of 553,253 duloxetine patients were included in the analysis.
DACONswere 1.27 (for CLBP, 1.26 for OA, 1.28 for FM, and 1.27 for DPNP, versus 1.44
for MDD (p0.0001 for each of the four pain conditions) and 1.32 for GAD. The
resultingADCs for the four pain conditions varied only slightly, from$6.99 for OA to
$7.13 for FM. ADC for MDD was notably higher ($8.00). The overall DACON for 2011
represented amodest decline from 2010,most notably for CLBP and FM (to 1.35 and
1.33, respectively; p0.0001 for both). CONCLUSIONS: 2011 DACONs and ADCs
varied little across the four chronic pain conditions for which duloxetine has been
approved for use by the FDA, all of which were significantly lower than for MDD.
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OBJECTIVES: To determine the association between depression treatment and
short-term health care expenditures using a nationally representative sample of
Medicare beneficiaries with chronic physical illnesses and depression.METHODS:
We employed a longitudinal design and used data from 2000 through 2005 of the
Medicare Current Beneficiary Survey, a nationally representative survey of Medi-
care benefi ciaries. Two years of observation, yielding five cohorts were used to
measure depression treatment in the baseline year andhealth care expenditures in
the second. The bivariate relationship between depression treatment in baseline
year and health care expenditures in the follow-up year was tested with t-tests.
Ordinary least squares (OLS) regressions on logged dollars were used to assess the
relationship between depression treatment and health care expenditures after
controlling for demographic, socio-economic, health status, and lifestyle risk
factors. RESULTS: Compared to no depression treatment ($16,795), the average
total expenditures were higher for those who used antidepressants only ($17,425)
and those who used psychotherapy with or without antidepressants ($19,733).
After controlling for the independent variables, antidepressant use and psycho-
therapy with or without antidepressants were associated with 21% and 31% in-
crease in total expenditures, respectively. For each expenditure type except for the
other category, we observed a statistically significant relationship between depres-
sion treatment and expenditures. CONCLUSIONS: Among the elderly with chronic
physical illnesses, depression treatment was associated with greater short-term
health care expenditures. Future research needs to examine whether this relation-
ship remains over a longer period of time.
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OBJECTIVES: The purpose of this studywas to compare adherence and persistence
for patients treated with duloxetine across several diagnoses categories: major
depressive disorder (MDD), fibromyalgia (FM), osteoarthritis (OA), and chronic
lower back pain (CLBP). METHODS: Patients age 18-64 initiating duloxetine treat-
ment during 2008 were identified in the Thomson Reuters MarketScan® Database.
The index event was defined as the first duloxetine prescription filled during the
study period with no duloxetine coverage during the previous 90 days. Patients
were assigned to disease-category cohorts on the basis of ICD-9 codes recorded on
medical claims dated within 1/- 3 month of the initial duloxetine prescription.
Adherence was measured over both 365- and 90-day post duloxetine initiation
periods as the percent of patients with a medication possession ratio 0.8. Persis-
tencewasmeasured over a 365-day post-initiation period as the percent of patients
with length of therapy  180 days. 2-tests were used to compare differences in
adherence and persistence across patient cohort. RESULTS: A total of 18,406 pa-
tients with one of the 4 identified diagnosis categories were identified as initiating
duloxetine in 2008: MDD (8,334), FM (3,630), OA (1,458) or CLBP (4,984). Adherence
was directionally greater among patientswithMDD (37.3%) versus FM (35.3%) or OA
(35.7%), and statistically significantly greater than CLBP (29.9%; p0.005). Compar-
isons of 90-day adherences were similar, with MDD (58.8%) directionally higher
than FM (54.1%) or OA (57.8%), and statistically significantly greater than CLBP
(50.0%; p0.005). Comparisons of persistencewere similar to adherence. For exam-
ple, persistence was 47.5% for MDD versus 38.7% for CLBP (p0.005).
CONCLUSIONS: Duloxetine adherence and persistence were similar among pa-
tients with MDD, FM, and OA, and significantly less among those with CLBP. These
relationships were consistent across variations in technical assumptions em-
ployed in calculating the study measures.
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OBJECTIVES: The study examined antidepressant utilization patterns and expen-
ditures in older adults in United States (US). METHODS: The study involved anal-
ysis of household and prescription files of the 2009 Medical Expenditure Panel
Survey (MEPS) data. The study sample included all older adults ( 50 years) with
depression. The analysis focused on antidepressant classes, namely selective se-
rotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAO),
phenylpiperazine and tetracyclics. Descriptive weighted analysis was performed
to examine antidepressant use patterns and prescription expenditures in commu-
nity dwelling depressed older adults. RESULTS: According to the 2009 MEPS, 11.36
million older adults were diagnosed with depression for an overall prevalence of
11.50% (95% CI, 12.34- 47.50). Most older adults with depression were 50-64 years of
age (66.79%), female (67.25%), and white (89.85%). Antidepressants were used by
78.61% (95% CI, 75.79- 81.43) of older adults with depression. The most prescribed
class of antidepressants was SSRIs (54.86%), followed by SNRIs (18.49%), phe-
nylpiperazine (7.92%), TCAs (6.96%) and tetracyclics (3.19%). Total antidepressant
prescriptionexpenditureswere $9.5 billion (95%CI, 8.3-10.7 billion).Highexpenditures
were found for SNRI ($4.3 billion, or 44.62% of antidepressant expenditures), followed
by SSRI ($3.5 billion, or 37.60%)), TCA ($172 million, or 1.8%), and phenylpiperazine
($131 million, or 1.37%). The average prescription price was also highest for SNRI
($181.56), followed by SSRI ($49.22), tetracyclic ($28.17), TCA ($19.13), and phe-
nylpiperazine ($13.64). CONCLUSIONS: Depression is highly prevalent among older
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